Financial incentives for cholesterol control may be cost-effective

September 14, 2018, Harvard T.H. Chan School of Public Health
Space-filling model of the Cholesterol molecule. Credit: RedAndr/Wikipedia

A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins (LDL) cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease (CVD), according to new research led by Harvard T.H. Chan School of Public Health.

The study showed that the shared incentive program provided reasonable value even when accounting for additional costs, such as electronic pill bottles to monitor drug adherence, more frequent cholesterol measurements, administrative expenses, and the actual cash incentive, which maxed out at $1,024 per year, split between the doctor and patient.

"Financial incentive interventions are only effective sometimes. When these programs show health benefits, the next question should be whether the health gains are worth the added costs, which is what we modeled in this study," said lead author Ankur Pandya, assistant professor of health decision science.

The study will be published on September 14, 2018 in JAMA Network Open.

CVD is the leading cause of death and in the U.S. The use of cholesterol-lowering drugs known as statins, which are cheap in their generic form, are proven to help prevent CVD. Yet long-term adherence to these medications is below 50%. One proposed strategy to improve adherence rates and lower LDL cholesterol—often referred to as "bad" cholesterol— is offering , but it's unclear if such programs are worth the costs.

To determine the cost-effectiveness of financial incentives, the Harvard Chan researchers, along with colleagues from Brigham and Women's Hospital and the Perelman School of Medicine at the University of Pennsylvania, developed a model-based analysis that simulated CVD progression.

They applied this analysis to data from a 2015 clinical trial involving statins in which were randomized to one of four groups: no financial incentives; financial incentives for only the patient; financial incentives for only the doctor; or a financial incentive shared between the patient and doctor. That study showed the shared incentive group was superior at reducing LDL cholesterol, but it did not examine whether the health gains represented good value given the added costs. The 2015 study was also limited in that it only followed up with patients three months after the study ended.

The CVD model, developed by corresponding and senior author Thomas Gaziano, was used by Chan School researchers to simulate lifetime CVD progression among a cohort of 1 million patients that mirrored the 2015 study population. Results showed that the shared incentives program had an incremental cost-effectiveness ratio (ICER) of $60,000 per quality-adjusted life year (QALY), a metric that reflects how much money is required to produce one year of high-quality life with a particular intervention. Under current standards, ICERs between $50,000 and $150,000 per QALY represent "intermediate value." The researchers said the findings demonstrated that the shared financial incentives program provided reasonable value for the health gains it produced compared with programs that offered financial incentives to only the patient or only the doctor or offered no financial incentive at all.

Importantly, the researchers found that the cost-effectiveness of the shared incentives intervention hinged on how long the LDL benefits persisted. They concluded that a large-scale study of the shared incentives strategy with at least five years of follow-up is warranted by the Centers for Medicare and Medicaid Services or private health care payers to test this strategy in a real-world setting.

"Combining financial incentives for providers and patients with advanced technologies to monitor compliance, including electronic pill bottles, has the potential to improve patient care while remaining cost-effective, and this strategy should be further evaluated," said Gaziano, assistant professor in the department of health policy and management at Harvard Chan School and director of the global cardiovascular policy and prevention unit at Brigham and Women's Hospital.

Explore further: Shared financial incentives for physicians and patients improve LDL cholesterol levels

More information: JAMA Network Open (2018). DOI: 10.1001/jamanetworkopen.2018.2008

Related Stories

Shared financial incentives for physicians and patients improve LDL cholesterol levels

November 8, 2015
In a study examining the effect of financial incentives to improve lipid levels among patients in primary care practices, shared financial incentives for physicians and patients, but not incentives to physicians or patients ...

Study asks: To improve patients' health, should you pay physicians, patients, or both?

November 8, 2015
Providing financial incentives to both primary care physicians and patients leads to a greater reduction in low-density lipoprotein (LDL) cholesterol in patients than paying only the physician or only the patient, according ...

New study finds financial incentives to help pregnant women stop smoking are highly cost-effective

November 12, 2015
The scientific journal Addiction has today published the first cost-effectiveness analysis of financial incentives to help pregnant women stop smoking. The report found that financial incentives are highly cost-effective, ...

Removal of GP incentives associated with decline in quality of care

September 7, 2018
The removal of financial incentives for doctors working in primary care is associated with a decline in performance on quality measures, according to new findings by researchers from the Universities of Dundee and Cambridge, ...

Financial incentives increased viral suppression in HIV-positive patients in care

June 19, 2017
Gift cards offered as financial incentives helped to increase viral suppression in human immunodeficiency virus (HIV)-positive patients in a community-based clinical trial in New York and Washington, D.C., two communities ...

It pays to be healthier: Targeted financial incentives for patients can lead to health behavior change

November 21, 2011
Financial incentives work for doctors. Could they work for patients, too? Could they encourage them to change unhealthy behaviors and use preventive health services more? In some cases, yes, according to Dr. Marita Lynagh ...

Recommended for you

Genetic analysis links obesity with diabetes, coronary artery disease

November 16, 2018
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published ...

Non-coding genetic variant could improve key vascular functions

November 15, 2018
Atherosclerotic disease, the slow and silent hardening and narrowing of the arteries, is a leading cause of mortality worldwide. It is responsible for more than 15 million deaths each year, including an estimated 610,000 ...

Study of two tribes sheds light on role of Western-influenced diet in blood pressure

November 14, 2018
A South American tribe living in near-total isolation with no Western dietary influences showed no increase in average blood pressure from age one to age 60, according to a study led by researchers at Johns Hopkins Bloomberg ...

Heart failure patients shouldn't stop meds even if condition improves: study

November 13, 2018
(HealthDay)—There's bad news for heart failure patients with dilated cardiomyopathy who'd like to stop taking their meds.

Bypass beats stents for diabetics with heart trouble: study

November 13, 2018
(HealthDay)—People with both diabetes and multiple clogged heart arteries live longer if they undergo bypass surgery rather than have their blood vessels reopened with stents, according to follow-up results from a landmark ...

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
not rated yet Sep 14, 2018
Wow. A study actually recommending bribing physicians and patients to take statins.

Bribing a health care professional is really frowned on.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.